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Comparison of AlloDerm and AlloMax Tissue
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John Kevin Grayson, DVM, PhD,þ and David E. Sahar, MD§
Background: Human acellular dermal matrices (HADMs) are used in a va-
riety of settings. AlloMax is a new HADM currently being used for breast
reconstruction and hernia repair. We compared the in vivo tissue integration
of AlloMax to AlloDerm, a well-studied HADM, in rats.
Methods: We implanted AlloDerm and AlloMax patches into subcutaneous
pockets on the backs of 32 male Sprague-Dawley rats. The animals were killed
after either 4 or 8 weeks, and the patches were recovered and stained for his-
topathologic analyses. Microscopic end points included patch thickness, vas-
cularization, tissue in-growth, fibroblast proliferation, and inflammation.
Results: All animals completed the study without complications or infection.
There were no significant differences in graft thicknesses at 4 and 8 weeks.
Microscopically, at 4 weeks, AlloDerm sections had significantly more mi-
crovessels than AlloMax (P = 0.02). This disparity increased by 8 weeks (P G
0.01). Similarly, we found greater tissue in-growth and fibroblast proliferation
in AlloDerm than AlloMax sections at 4 (P G 0.01) and at 8 (P G 0.01) weeks.
Inflammatory infiltrates consisted of lymphocytes, histiocytes, eosinophils,
and plasma cells. Deep graft infiltration by predominately lymphocytic inflam-
matory cells was significantly higher in AlloDerm than AlloMax grafts at 4
(P = 0.01) and 8 (P = 0.02) weeks. Graft necrosis was uncommon, but mar-
ginal fibrosis was similar in both.
Conclusions: AlloDerm grafts had greater neovascularization, tissue infiltra-
tion, fibroblast proliferation, and inflammatory reaction than AlloMax grafts
when placed subcutaneously in rats. AlloDerm may be better incorporated
than AlloMax when placed in vivo.
Key Words: AlloDerm, AlloMax, human acellular dermis, biocompatible
materials, collagen, tissue scaffolds, materials testing, regenerative medicine
(Ann Plast Surg 2013;00: 00Y00)
Human acellular dermal matrices (HADMs) have been in clini-cal use for more than 15 years and are used in a variety of re-
constructive procedures. Surgeons may now choose from several
HADMs that, at first glance, appear remarkably similar. All HADMs
are derived from cadaveric tissue, must undergo decellularization to
prevent immunogenic rejection, and appear to promote tissue in-
growth with neovascularization after implantation. Despite these sim-
ilarities, each HADM has distinguishing properties stemming from
the various processing methods for the cadaveric tissue. These pro-
prietary decellularization and sterilization processes lead to different
storage requirements, shelf lives, intraoperative preparation, and cost.
What matters most though is actual product performance, and most
HADMs lack comparative clinical and experimental evidence of their
capabilities.
The purpose of our study was to compare the tissue incorpo-
ration of a new HADM, AlloMax (CR Bard/Davol Inc, Cranston,
RI), to the widely used AlloDerm (LifeCell Corp, Branchburg, NJ).
AlloDerm has been well studied in both animal experiments and
human clinical research. Previous animal studies have shown that
AlloDerm promotes tissue integration and neovascular-ization.1Y6
Clinical reports have shown that AlloDerm can provide satisfactory
cosmetic outcomes in a variety of reconstructive procedures.7Y10
Other studies, though, have raised concerns over the performance
of AlloDerm. Because AlloDerm is not terminally sterilized during
processing, controversy has arisen regarding increased infection rates
in sterile procedures such as breast reconstruction.11 AlloDerm has
also developed a reputation for excessive laxity resulting in recurrent
hernias when used for abdominal wall reconstruction.8,12 Other
HADM products such as AlloMax have been developed to address
these issues. To counter concerns of contamination, AlloMax is one
of the 2 currently marketed HADMs to undergo terminal steriliza-
tion. AlloMax also claims to cause less stretch. Do the unique
AlloMax preparation processes, however, inhibit in vivo tissue in-
corporation? Our study is the first to compare the in vivo perfor-
mance of AlloMax with AlloDerm.
MATERIALS AND METHODS
This study was approved by the Institutional Animal Care and
Use Committee at David Grant USAF Medical Center. All animals
received humane care in compliance with the Guide for the Care and
Use of Laboratory Animals (National Institutes of Health publica-
tion 86Y23, revised 1996). All animal handling and research were
conducted in our facility, which is accredited by the Association for
the Assessment and Accreditation of Laboratory Animal Care Inter-
national. No author was affiliated with Lifecell or Bard.
Animal Handling and Preparation
We used 32 adult male Sprague-Dawley rats, weighing [mean
(SEM)] 431 (24) g. The animals were fed a commercial diet and
observed for 10 days before initiating the study. Food was withheld
for 1 hour before surgery to ensure that food material was not present
in the mouth. The rats were initially anesthetized with 5% isoflurane
in oxygen at 1 L/min in an induction chamber. Anesthesia was main-
tained with 2% isoflurane in 1 L/min oxygen delivered by face mask
to effect. After clipping the hair over the rat’s dorsum, the skin was
prepared by alternating 3 chlorhexidine scrub and sterile saline rinses.
Surgical Procedure
AlloMax and AlloDerm grafts of comparable thickness (both
listed as 0.8Y1.8 mm) were used. Despite the similar thickness listed
on the packaging, the AlloMax we used grossly appeared thicker than
AlloDerm. The grafts were prepared according to the manufacturer’s
instructions during surgery. AlloDerm was rehydrated in a 2-step
process. The AlloDerm was first placed in a warm saline bath until
the paper backing separated from the AlloDerm. The material was
then submerged for at least 15 minutes in another saline bath at which
point the graft was soft and pliable. AlloMax was rehydrated by
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submerging the implant in a saline solution for 5 minutes, at which
point the material was supple and pliable. The surgery was performed
in a manner similar to the previous study of Richter et al5 evaluat-
ing dermal matrices in rats. A 4-cm midline dorsal skin incision was
made. Flaps were raised between the panniculus carnosus and the deep
muscular fascia. A piece of AlloDerm was fashioned into a 1  1-cm
patch and placed on the right side of the pocket. Care was taken to
ensure that the dermal side faced the underlying muscular fascia. A
piece of AlloMax was identically fashioned and placed on the left side
of the pocket. The implants were not sutured in place to prevent any
inflammatory reaction from the suture material interfering with the
results. The fascia was closed with 4-0 polyglactin 910 suture (Vicryl;
Ethicon, Inc, Somerville, NJ), and the skin was closed with 5-0 poli-
glecaprone 25 (Monocryl; Ethicon, Inc) in a running subcuticular pat-
tern. Cyanoacrylate adhesive (Vetbond; 3M Inc, Minneapolis, MN)
was used to reinforce the skin closure. After surgery, the rats were
maintained in a warm environment until completely recovered from
the procedure, at which time they were returned to their normal hous-
ing. The rats received buprenorphine at 0.01 to 0.05 mg/kg subcuta-
neously every 12 hours for 48 hours and then ad libitum.
Data Collection
Half of the rats were killed at 4 weeks, whereas the remain-
ing rats were killed at 8 weeks. Rats were euthanized by carbon di-
oxide inhalation in accordance with the 2007 AVMA Guidelines on
Euthanasia. The implanted materials were removed en bloc and pre-
served in 10% formalin before histologic processing. Sections were
cut from the center of each graft, sectioned at 4 Km, and routinely
processed with hematoxylin and eosin and Masson trichrome stains.
Measurements of graft thickness were carried out with image analy-
sis software (Image Pro Express v 6.0; Media Cybernetics, Bethesda,
MD). Histologic analyses were adapted from previously reported
methods,4,5 including the mean number of microvessels in 3 high-
power fields from the most vascular areas on each slide, the estimated
area of tissue in-growth on each slide, and the estimated area occu-
pied by fibroblasts on each slide. Each slide was also evaluated by a
pathologist (B.C.) blinded to time point and material, who reviewed
sections for the presence of necrosis, fibrosis, surrounding granula-
tion tissue, foreign body giant cell reaction, and type and location
of inflammatory cells. Fibrosis was defined as dense collagen and
fibroblastic reaction not associated with suture material. The pres-
ence of granulation tissue was assessed in a semiquantitative fashion
as none, one focus, or multiple foci, to include presence of circum-
ferential vascular proliferation and inflammation surrounding the
graft. The location of leukocytes was evaluated based on presence of
leukocytes at the periphery, superficial infiltration, or deep infiltra-
tion of the graft. Because peripheral inflammation and superficial
infiltration were difficult to separate in practice, these 2 categories
were combined. The graft was only considered to have deep infil-
tration by leukocytes if the cells were seen in the center of the graft,
not associated with probable fibrosis and reaction secondary to su-
ture material.
Statistical Analysis
The primary outcomes were neovascularization, tissue infil-
tration, and degree of inflammation. All data are presented as mean
(SEM). Analysis of variance was used for numerical data analysis,
and count data were analyzed with W2 statistics, both conducted with
commercial statistical software (STATA v10; StataCorp, College Sta-
tion, Tx), with P G 0.05 being considered statistically significant.
RESULTS
All rats survived until the time of planned kill. No gross signs
of infection or implant rejection occurred in any rat; all surgical
wounds appeared well healed. During the implant harvest, the Allo-
Derm and AlloMax implants were readily identifiable and incorpo-
rated with the surrounding tissue at both 4 and 8 weeks. In situ, blood
vessels could be seen crossing both graft materials by 4 weeks. Mean
(SEM) graft thicknesses for AlloDerm were 1.33 (0.08) mm at
4 weeks and 1.7 (0.06) mm at 8 weeks (P = 0.56). Comparable values
for AlloMax were 1.5 (0.06) and 1.6 (0.05), respectively (P = 0.48;
see Figure 1 and Figure 2 for representative sections). The overall
graft appearance was unaltered from the time of implantation; his-
tologic evaluation, however, showed significant differences between
the 2 materials.
Figure 3 indicates that neovascularization was evident in both
AlloDerm and AlloMax patches at 4 weeks, although AlloDerm had
significantly greater neovascularization than AlloMax at 4 and
8 weeks (P = 0.02 and P G 0.01, respectively). By 8 weeks, AlloDerm
FIGURE 1. AlloDerm cross-section 4 weeks after implantation.
Note the extensive tissue infiltration and inflammatory
response. Masson trichrome stain, original magnification 4.
Bar = 50 K.
FIGURE 2. AlloMax cross-section 4 weeks after implantation.
Note the minimal tissue infiltration and marginal inflammatory
response. Masson trichrome stain, original magnification 4.
Bar = 50 K.
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patches had significantly more microvessels than what were present
at 4 weeks (P G 0.01). However, this same trend was not observed in
the AlloMax patches, and there were no significant differences in
neovascularization of 4- and 8-week AlloMax patches (P = 0.35).
AlloDerm patches also had significantly more cellular infil-
tration (see Fig. 4) compared with AlloMax patches at 4 and 8 weeks
(P G 0.01). AlloDerm patches also showed a significant increase
in cellular infiltration between 4 and 8 weeks (P G 0.01), whereas
the cellularity of AlloMax patches remained essentially the same be-
tween the 2 time points (P = 0.53). In addition, the estimated area
occupied by fibroblasts in the AlloDerm patches (see Fig. 5) was
significantly greater at 4 and 8 weeks than in the AlloMax patches
(P G 0.01). The area occupied by fibroblasts increased significantly
between 4 and 8 weeks in the AlloDerm patches (P = 0.03), whereas
the area occupied by fibroblasts declined in the AlloMax patches,
although not significantly (P = 0.79).
Necrosis was only observed in 1 AlloDerm graft, at 8 weeks.
In the 4-week grafts, fibrosis was observed in 0 (0%) of 16 AlloDerm
grafts and 3 (18.8%) of 16 AlloMax grafts (P = 0.82). In the 8-week
grafts, fibrosis was observed in 11 (68.8%) of 16 AlloDerm grafts
and 8 (50%) of 16 AlloMax grafts (P = 0.28). Foreign body giant cell
reaction was identified in all AlloDerm and nearly all AlloMax grafts
at both 4 and 8 weeks. All AlloDerm and AlloMax grafts at both
4 and 8 weeks had superficial inflammatory infiltrates consisting of
lymphocytes, histiocytes, eosinophils, and plasma cells. Deep infil-
tration of the grafts by lymphocyte-predominant mixed inflamma-
tory cells was observed in 10 (62.5%) of 16 AlloDerm and 3 (18.8%)
of 16 AlloMax grafts at 4 weeks (P = 0.01). Deep infiltration of the
zgrafts by lymphocyte-predominant mixed inflammatory cells was
observed in 5 (31.2%) of 16 AlloDerm grafts and 0 (0%) of 16
AlloMax grafts at 8 weeks (P = 0.02). Although the presence of in-
flammatory cells was similar in both groups at 4 weeks, by 8 weeks,
AlloDerm exhibited significantly more inflammatory cells than Allo-
Max, mainly because of the decrease in cells in the AlloMax group.
The presence of eosinophils was similar for both groups at 4 and
8 weeks.
DISCUSSION
Our study showed that AlloMax stimulated tissue in-growth
and neovascularization. This tissue incorporation, however, was
limited and did not appear to increase after 4 weeks. By contrast,
AlloDerm tissue integration appeared more pronounced than Allo-
Max at 4 weeks and continued to progress at 8 weeks. Neither ma-
terial caused any complications.
Since AlloDerm first appeared on the market in 1995, several
other HADM have been developed including FlexHD (Ethicon Inc,
Somerville, NJ), DermaMatrix (Synthes Inc, West Chester, PA), and
AlloMax. These competitors claim a few advantages over AlloDerm,
including less intraoperative preparation time and the truly sterile
nature of their product. AlloDerm itself has evolved over the years.
Per current handling instructions, AlloDerm no longer needs to be
refrigerated during storage, and its applications have broadened from
skin grafting to other procedures such as breast and abdominal wall
reconstruction. Despite these improvements, some questions remain
over the clinical performance of AlloDerm implants. A recent study
cited increased wound infections when using AlloDerm compared
with other breast reconstruction techniques, and several reports cite
the propensity for hernia recurrence and abdominal wall laxity with
AlloDerm.8,11,12 AlloDerm use is also associated with ‘‘red breast
syndrome,’’ a sterile, chronic cellulitis that resolves without treatment
but results in clinical confusion and patient discomfort. This may be
FIGURE 3. Mean number of vessels per high-power field.
FIGURE 4. Mean percent area with tissue infiltration per
high-power field.
FIGURE 5. Mean area occupied by fibroblasts per
high-power field.
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due to the AlloDerm preparation process, inflammatory mediators
from neovascularization, or simply reversing the proper orientation of
the product at implantation (ie, placing the dermal side on the least
vascularized tissue).13Y15 Although other HADMs have also been as-
sociated with red breast syndrome, its occurrence has not been docu-
mented in NeoForm or AlloMax.
AlloMax addresses these concerns by undergoing a terminal
sterilization process, claiming less ex vivo elasticity than AlloDerm,
and not mandating a specific polarity (and thus preventing a possible
cause of red breast syndrome). It is unknown, though, if the AlloMax
preparation processes inhibit native tissue integration. Even when
dermal matrices share a common source, the proprietary preparation
processes may greatly affect in vivo tissue integration and perfor-
mance.16 Different graft preparation methods (such as collagen cross-
linking) can trigger different host immune responses, resulting in
either reconstructive remodeling or chronic inflammation.16 None-
theless, other studies show little difference in tissue incorporation
despite using dermal matrices from different species and undergoing
different preparation processes.1,3,4,7 Nonetheless, prominent clinical
issues such as AlloDerm in vivo laxity after remodeling may be an-
ticipated by animal studies such as ours.4,17
NeoForm, the only other terminally sterilized HADM avail-
able, has shown promising initial results when used in breast recon-
struction, but no studies until now have provided evidence of in vivo
tissue integration of AlloMax.18 The only other studies discussing
AlloMax showed a marked discrepancy in human macrophage re-
sponse and cytokine production in comparison with AlloDerm in vitro.
AlloMax generated a significantly greater amount of interleukin (IL)
1A, IL-8, IL-6, and VEGF.19 These in vitro results would suggest a
greater in vivo inflammatory response to AlloMax. This increased
cytokine production could either lead to a chronic inflammatory re-
sponse with encapsulation or more robust remodeling. Our study sug-
gests that AlloMax processing may retard tissue remodeling when
compared with AlloDerm. The agents used to decellularize AlloMax
may account for these differences.20 A review article by Crapo et al21
provides an overview of how these different agents can alter biologic
materials and possibly inhibit in vivo remodeling. Sodium hydroxide
can damage collagen and remove growth factors. Acetone, which also
is used for delipidation, may cross-link collagen. Finally, the gamma
radiation used to sterilize the product may damage the extracellular
matrix as well. The preparation methods for AlloDerm, however, may
also affect its performance.20,21 Sodium deoxycholate can remove gly-
cosaminoglycans, and freeze drying may damage the extracellular
matrix. Whatever the key discrepancy is, our study shows that AlloMax
promotes less tissue remodeling than AlloDerm. Although the AlloMax
grafts we used also grossly appeared thicker than AlloDerm, the lack
of tissue remodeling in the AlloMax grafts suggests that the thick-
ness was not the reason for these differences.
There are several possible clinical implications with these
findings. The lack of ongoing remodeling suggests that AlloMax
may eventually become encapsulated with collagen like other for-
eign bodies and remain unabsorbed. The recent emphasis on using
HADM as biologic scaffolds for regenerative medicine would make
AlloMax a less suitable material than AlloDerm. The comparative
lack of neovascularization would also render AlloMax less infection
resistant compared with other biologic implants such as AlloDerm.
The relative paucity of cellular infiltration, however, may have its
benefits. The relatively rapid reabsorption of AlloDerm may make it
less suitable for reconstructive procedures where durability is es-
sential, such as abdominal wall reconstruction. Facial reconstructive
procedures where a preserved contour is desired may also warrant a
more durable material than AlloDerm.17 AlloMax may thus provide
greater tensile strength and be prone to less stretching than Allo-
Derm, although we did not test these properties in our study. With
the increased presence of inflammatory cells in AlloDerm, studies
taken beyond an 8-week end point could show AlloMax to be a more
durable material. Regardless, AlloMax and AlloDerm performance in
humans may be closer than what our animal study suggests. Despite
the rigorous decellularization and sterilization processes used, some
HADMs still retain some donor DNA and antigens.22 This may retard
tissue integration in other species but provide less impedance in hu-
mans. Implantation longer than 8 weeks in humans may show fur-
ther cellular infiltration of AlloMax, although our results with rats
showed a lack of tissue remodeling after 4 weeks of implantation.
Further studies must be done examining the tissue integration, infec-
tion resistance, and clinical application of AlloMax.
In conclusion, AlloMax does promote tissue integration of
native tissue with minimal to no recipient site morbidity. The in vivo
tissue integration of AlloDerm, however, is significantly greater than
AlloMax in rats, and AlloMax’s tissue integration appears static
4 weeks after implantation.
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